ASO VISUAL ABSTRACT

ASO Visual Abstract: Outcomes of Sentinel Node Biopsy in Women with Breast Cancer Following Neoadjuvant Therapy—Systematic Review and Meta-Analysis of Real-World Data

Shi-Qian Lin, MS¹, Nguyen-Phong Vo, MD², Yu-Chun Yen, MS³, and Ka-Wai Tam, MD, PhD^{4,5,6,7}

¹School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; ²International PhD Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; ³Biostatistics Center, Office of Data Science, Taipei Medical University, Taipei, Taiwan; ⁴Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan; ⁵Division of General Surgery, Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; ⁶Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan; ⁷Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan

The accuracy of sentinel lymph node biopsy (SLNB) following neoadjuvant therapy (NAT) in patients with breast cancer is inconclusive. Current real-world evidence revealed that the false negative rate (FNR) of SLNB and identification rate of sentinel lymph nodes (SLNs) after

NAT were 11.8% and 90.6%, respectively. Patients with estrogen receptor (ER)-negative status and fewer than three SLNs removed had a significantly higher FNR (<https://doi.org/10.1245/s10434-021-11297-z>).